Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

5 months ago 17
Read Entire Article
  1. Homepage
  2. Finance
  3. Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Related

US mulls equity stakes in chipmakers receiving CHIPS Act Funds - Reuters

US mulls equity stakes in chipmakers receiving CHIPS Act Fun...

8 minutes ago 0
Cardinal Health CEO Hollar sells $16m in shares

Cardinal Health CEO Hollar sells $16m in shares

8 minutes ago 0
Cardinal Health CEO Mason sells $6.1m in shares

Cardinal Health CEO Mason sells $6.1m in shares

8 minutes ago 0

Trending

1. napheesa collier
2. yankees game
3. stefanos tsitsipas
4. yankees game today
5. john kruk
6. mark vientos
7. bucknell university
8. agt
9. fluminense vs américa de cali
10. fluminense - américa

Popular

College football by the odds: Vegas picks and preview of Ohio State vs. Notre Dame

College football by the odds: Vegas picks and preview of Ohi...

6 months ago 464
What to do in Las Vegas this week: January 2-8

What to do in Las Vegas this week: January 2-8

7 months ago 226
Australian whose blood saved 2.4 million babies dies

Australian whose blood saved 2.4 million babies dies

5 months ago 193
Taiwan slightly cuts 2025 GDP growth outlook amid Trump tariffs concern

Taiwan slightly cuts 2025 GDP growth outlook amid Trump tari...

5 months ago 169
What is Tren de Aragua, the Venezuelan gang targeted by Trump?

What is Tren de Aragua, the Venezuelan gang targeted by Trum...

5 months ago 168
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Sincity Press 2025. All rights are reserved